A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Moderate to Severe Atopic Dermatitis (AD)

Last updated: November 16, 2025
Sponsor: Bambusa Therapeutics
Overall Status: Active - Recruiting

Phase

1

Condition

Atopic Dermatitis

Dermatitis, Atopic

Eczema (Atopic Dermatitis)

Treatment

BBT001

Placebo

Clinical Study ID

NCT07239947
BBT001-002
  • Ages 18-65
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

This is a Phase 1, randomized, blinded, placebo controlled, single ascending dose (SAD) study of BBT001 in healthy volunteers (HVs) and adult patients with moderate to severe Atopic Dermatitis (AD).

Eligibility Criteria

Inclusion

Key Inclusion Criteria ( Part A and B):

  1. Age of 18-65 years.

  2. Body mass index between 18-28 kg/m², capped at 120 kg.

  3. Negative pregnancy tests for women of childbearing potential.

  4. Willingness to refrain from alcohol consumption for 24 hours prior to each study visit.

  5. Non-smokers, healthy current smokers (≤5 cigarettes/day), or ex-smokers.

  6. Adequate contraception use (for men and women of childbearing potential).

  7. No clinically significant abnormalities or history of relevant diseases.

Key Inclusion Criteria (Part B only):

  1. Must have dermatologist-confirmed chronic atopic dermatitis (≥12 months). Inadequate response to topical treatments or where they are medically inadvisable.

  2. Moderate to severe atopic dermatitis

  3. Validated investigator's global assessment for atopic dermatitis (vIGA-ADTM) score ≥3

  4. Atopic lesions cover ≥10% of body surface area (BSA)

  5. Average peak pruritus numeric rating scale (PP-NRS) score ≥4 in the 7 days before randomization.

  6. Eczema Area and Severity Index (EASI) score ≥16 at screening and randomization visits.

Key Exclusion Criteria for (Part A&B)

  1. Significant health issues, such as: diabetes, positive tests for human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis B surface antigen (HBsAg), immunodeficiencies, autoimmune diseases, or cancer, history of conditions predisposing to infections.

  2. History of major metabolic, dermatological, liver, kidney, hematological, or other significant disorders.

  3. Clinically relevant abnormal lab results, including low blood counts, liver issues, or abnormal kidney function.

  4. Positive drug/alcohol tests or abnormal vital signs at screening or Day -1.

  5. Abnormal Electrocardiogram (ECG) findings

  6. History of drug/alcohol abuse in the past 2 years.

  7. Donated >500mL blood within 2 months of screening.

  8. History of severe allergic reactions or hypersensitivity.

Key Exclusion Criteria for (Part B only)

  1. Skin diseases other than atopic dermatitis, significant tattoos, or scarring.

  2. Receipt of immunoglobulin or blood products within 30 days.

  3. Atopic dermatitis with ocular symptoms or chronic ocular steroid use.

  4. Chronic pruritus from conditions other than atopic dermatitis.

  5. Acute/treated infections or chronic skin infections.

  6. Current use of sedating antihistamines or corticosteroids.

Study Design

Total Participants: 63
Treatment Group(s): 2
Primary Treatment: BBT001
Phase: 1
Study Start date:
August 09, 2025
Estimated Completion Date:
March 26, 2027

Study Description

The study consists of two parts:

Part A (single dose in HVs in sequential ascending dose cohorts, SAD in HVs part) Part B (seven repeated doses in patients with moderate to severe AD, multiple ascending Dose in patients part)

Connect with a study center

  • The Second Hospital of Anhui Medical Univesity

    Hefei 1808722, Anhui 1818058 230601
    China

    Active - Recruiting

  • The Second Affiliated Hospital of Wannan Medical College

    Wuhu 1791236, Anhui 1818058 241001
    China

    Site Not Available

  • Peking University People's Hospital

    Beijing 1816670, Beijing Municipality 2038349 100032
    China

    Site Not Available

  • Dermatology Hospital of Southern Medical University

    Guangzhou 1809858, Guangdong 1809935 510440
    China

    Site Not Available

  • The Second Xiangya Hospital of Central South University

    Changsha 1815577, Hunan 1806691 410011
    China

    Site Not Available

  • Wuxi Second People's Hospital

    Wuxi 1790923, Jiangsu 1806260 214002
    China

    Site Not Available

  • Jiangsu University Affiliated Hospital

    Zhenjiang 1784642, Jiangsu 1806260 212001
    China

    Site Not Available

  • Jiangxi Provincial Dermatology Hospital

    Nanchang 1800163, Jiangxi 1806222 330000
    China

    Site Not Available

  • Shandong Provincial Hospital for Skin Diseases

    Jinan 1805753, Shandong 1796328 250011
    China

    Site Not Available

  • Shanghai Dermatology Hospital

    Shanghai 1796236, Shanghai Municipality 1796231 200050
    China

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.